Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2007-09-27
2010-11-16
Bristol, Lynn (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S145100, C424S158100
Reexamination Certificate
active
07833527
ABSTRACT:
The present invention relates to IL-17 Receptor A antigen binding proteins, such as antibodies, and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation.
REFERENCES:
patent: 5116964 (1992-05-01), Capon et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5703088 (1997-12-01), Sharpe et al.
patent: 5716805 (1998-02-01), Srinivasan et al.
patent: 5869286 (1999-02-01), Yao et al.
patent: 6043344 (2000-03-01), Jacobs et al.
patent: 6072033 (2000-06-01), Yao et al.
patent: 6072037 (2000-06-01), Yao et al.
patent: 6083906 (2000-07-01), Troutt
patent: 6096305 (2000-08-01), Yao et al.
patent: 6100235 (2000-08-01), Yao et al.
patent: 6114598 (2000-09-01), Kucherlapati et al.
patent: 6162963 (2000-12-01), Kucherlapati et al.
patent: 6191104 (2001-02-01), Spriggs et al.
patent: 6197525 (2001-03-01), Yao et al.
patent: 6406867 (2002-06-01), Yu et al.
patent: 6680057 (2004-01-01), Yao et al.
patent: 6793919 (2004-09-01), Mohler
patent: 6833268 (2004-12-01), Green et al.
patent: 7049426 (2006-05-01), Green et al.
patent: 7064244 (2006-06-01), Jakobovits et al.
patent: 2009/0074758 (2009-03-01), Tocker et al.
patent: WO 95/18826 (1995-07-01), None
patent: WO 96/29408 (1996-09-01), None
patent: WO 97/04097 (1997-02-01), None
patent: WO 98/23284 (1998-06-01), None
patent: WO 99/14240 (1999-03-01), None
patent: WO 99/60127 (1999-11-01), None
patent: WO 00/15759 (2000-03-01), None
patent: WO 00/55204 (2000-09-01), None
patent: WO 01/68705 (2001-09-01), None
patent: WO 01/68859 (2001-09-01), None
patent: WO 2004/002519 (2004-01-01), None
patent: WO 2005/063290 (2005-07-01), None
patent: WO 2006/054059 (2006-05-01), None
patent: WO 2006/088925 (2006-08-01), None
About.com.arthritis (definition for “DMARDS”, pp. 1-2; Jul. 2, 2009).
Webmd.com (definition for “DMARDS”; pp. 1-3; Jul. 2, 2009).
Dogra e tal. (Indian J. Dermatol. Venereol. Leprol. 72(4): 256-264 (2006).
Van de Kerkhof (JEADV 20:639-650 (2006)).
Nickolof et al. (J. Clin. Invest. 113(12): 1664-1675 (2004)).
Peterson (Pharmacol. & Toxicol. 99:104-115 (2006).
ClinicalTrials.gov (AMG 827; NCT00975637; pp. 1-4, Dec. 28, 2009).
Chabaud, M. and Miossec, P., “The combination of tumor necrosis factor α blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model,”Arthritis Rheum, 44(6):1293-1303, 2001.
Charles et al., “Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis,”J Immunol, 163:1521-1528, 1999.
Cannetti et al., “IL-18 enhances collagen-induced arthritis by recruiting neutrophils via TNF-α and leukotriene B4,”J Immunol, 171:1009-1015, 2003.
Cunnane et al., “Serum amyloid A in the assessment of early inflammatory arthritis”,J. Rheumatol, 27:58-63, 2000.
Fujino et al., “Increased expression of in terleukin 17 in inflammatory bowel disease,”Gut, 52:65-70, 2003.
Green, L. and Jakobovits, A., “Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes,”J Exp Med, 188(3):483-495, 1998.
Green et al., “Antigen-specific human monoclonal antibodies from mice engineered with huma Ig heavy and light chain YACs,”Nat Genet, 7:13-21, 1994.
Harrington et al., “Interleukin 17-producing CD4+effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages,”Nat Immunol, 6(11):1123-1132, 2005.
Jia et al., “A novel method of multiplexed competitive antibody binning for the characterization of monoclonal antibodies,”J Immunol Methods, 288:91-98, 2004.
Kauffman et al., “A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis,”J Invest Dermatol, 123:1037-1044, 2004.
Kimura, A. et al., “IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells,”Proc Natl Acad Sci, USA, 104(29):12099-12104, 2007.
Kolls, J. and Linden, A., “Interleukin-17 family members and inflammation,”Immunity, 21:467-476, 2004.
Konishi et al., “Il-18 contributes to the spontaneous development of atopic dermatitis-like inflammatory skin lesion independently of IgE/stat6 under specific pathogen-free conditions,”Proc Natl Acad Sci, USA, 99(17):11340-11345, 2002.
Langrish et al., “IL-23 drives a pathogenic T cell population that induces autoimmune inflammation,”J Exp Med, 201(2):233-240, 2005.
Li et al., “The expression of interleukin-17, interferon-gamma, and macrophage inflammatory protein-3 alpha mRNA in patients with psoriasis vulgaris”,J Huazhong Univ Sci Technolog Med Sci, 24(3):294-296, 2004.
Lindén et al., “Airway neutrophils and interleukin-17,”Eur Respir J, 15:973-977, 2000.
Lubberts et al., “IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis,”J Immunol, 167:1004-1013, 2001.
Lubberts et al., “IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-κB ligand/osteoprotegerin balance,”J Immunol, 170:2655-2662, 2003.
Lubberts et al., “The role of T cell interleukin-17 in conducting destructive arthritis: lessons from animal models,”Arthritis Res Ther, 7:29-37, 2005.
Mangan et al., “Transforming growth factor-β induces development of the TH17 lineage,”Nature, 441:231-234, 2006.
Mannon et al., “Anti-interleukin-12 antibody for active Crohn's disease,”N Engl J Med, 351:2069-2080, 2004.
Matusevicius et al., “Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis”,Mult Scler, 5:101-104, 1999.
McAllister et al., “Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-α and granulocyte colony-stimulating factor in bronchial epithelium: Implications for airway inflammation in cystic fibrosis,”J Immunol, 175:404-412, 2005.
Mendez et al., “Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice,”Nat Genet, 15:146-156, 1997.
Miossec, P., “Interleukin-17 in rheumatoid arthritis,”Arthritis&Rhem, 48(3):594-601, 2003.
Molet et al., “IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines,”J Allergy Clin Immunol, 108(3):431-438, 2001.
Nakae et al., “IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist,”Proc Natl Aced Sci, USA, 100(10):5986-5990, 2003.
Nakae et al., “Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice,”J Immunol, 171:6173-6177, 2003.
Nanevicz et al., “;Mechanisms of thrombin receptor agonist specificity,”J Biol Chem, 270(37):21619-21625, 1995.
Numasaki et al., “Regulatory roles of IL-17 and IL-17F in G-CSF production by lung microvascular endothelial cells stimulated with IL-1β and/or TNF-α,”Immunol Lett, 95:97-104, 2004.
Oda et al., “Interleukin-17F induces pulmonary neutrophilia and amplifies antigen-induced allergic response,”Am J Respir Crit Care Med, 171:12-18, 2005.
Park et al., “A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17,”Nat Immunol, 6(11):1133-1141, 2005.
Stemmer et al., “Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides,”Gene, 164:49-53, 1995.
Toy et al., “Cutting Edge: Interleukin 17 signals through a heteromeric receptor complex,”J Immunol, 177:36-39, 2006.
Yao et al., “Herpesvirus sai
Fitzpatrick David
Peschon Jacques J.
Tocker Joel
Amgen Inc.
Bristol Lynn
Klaniecki James E.
LandOfFree
Methods of treating psoriasis using IL-17 Receptor A antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating psoriasis using IL-17 Receptor A antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating psoriasis using IL-17 Receptor A antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4161961